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Summary
Radiotherapy—despite being a local therapy that meanwhile is characterized by an im-
pressively high degree of spatial accuracy—can stimulate systemic phenomena which oc-
casionally lead to regression and rejection of non- irradiated, distant tumor lesions. These 
abscopal effects of local irradiation have been observed in sporadic clinical case reports 
since the beginning of the 20th century, and extensive preclinical work has contributed to 
identify systemic anti- tumor immune responses as the underlying driving forces. Although 
abscopal tumor regression still remains a rare event in the radiotherapeutic routine, in-
creasing numbers of cases are being reported, particularly since the clinical implementa-
tion of immune checkpoint inhibiting agents. Accordingly, interests to systematically 
exploit the therapeutic potential of radiotherapy- stimulated systemic responses are con-
stantly growing. The present review briefly delineates the history of radiotherapy- induced 
abscopal effects and the activation of systemic anti- tumor immune responses by local ir-
radiation. We discuss preclinical and clinical reports with specific focus on the correspond-
ing controversies, and we propose issues that should be addressed in the future in order 
to narrow the gap between preclinical knowledge and clinical experiences.
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1  | INTRODUCTION
Together with surgery and chemotherapy, radiotherapy (RT) plays a cen-
tral role in oncological treatment regimens. More than 60% of all can-
cer patients receive RT at one point during their medical attendance.1 
Traditionally, the efficacy of RT has been exclusively credited to its abil-
ity to induce cancer cell death and the notion that tumors are more 
prone to damage induced by ionizing radiation (IR) than non- malignant, 
normal tissues. According to the concept of the four R’s of radiotherapy, 
repair (of IR- induced damage), reoxygenation, redistribution (to other 
cell cycle phases), and regeneration are the major determinants of a 
tissue’s response toward IR.2 Importantly, tumors and non- malignant 
tissues are considered to differ in these characteristics, thus forming 
the rationale for the use of fractionated irradiation regimens with daily 
fractions over a period of 3- 6 weeks in the clinical routine.
It needs to be stressed that in the majority of all cases RT is ap-
plied in local settings with a high degree of spatial precision and the 
cardinal aim to achieve locoregional tumor control. However, there is 
accumulating evidence that—although applied locally—RT can induce 
systemic anti- tumor responses leading to regression and rejection of 
non- irradiated, distant tumor lesions. Collectively, these observations 
have been summarized under the term ‘abscopal effects of RT’, and 
meanwhile it is well accepted that immune mechanisms are the un-
derlying driving forces. For distinct chemotherapeutics, the induction 
of such systemic, immune- mediated effects has been extensively an-
alyzed by the groups of G. Kroemer and L. ZitvogeI.3–5 The present 
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review focuses on systemic, abscopal effects stimulated by local RT. 
We will briefly outline the history of RT- induced abscopal effects as 
well as the RT- mediated activation of the immune system, and we will 
present and discuss preclinical and clinical reports with particular em-
phasis on their discrepancies and issues that should be considered in 
the future.
2  | THE HISTORY OF RADIOTHERAPY- 
INDUCED ABSCOPAL EFFECTS
It was W.C. Roentgen who announced the discovery of X- rays in 
November 1895,6 published shortly afterward in 1896 7 (Figure 1). Only 
a few months after Roentgen’s discovery, E.H. Grubbe applied X- rays 
therapeutically to the first patient who was treated for breast cancer in 
January 1896.8 Since then, RT has undergone continuous improvements, 
and nowadays different irradiation regimens, including conventionally 
fractionated RT, hypofractionated settings, and ablative RT, are clinically 
available. Most patients receive fractionated RT with daily doses of 1.8- 
2.0 Gy 5 times per week up to a total dose of 45- 70 Gy. As mentioned 
before, the rationale for dose fractionation derives from radiobiological 
considerations: Repair of IR- mediated damage and regeneration mecha-
nisms support recovery of the normal tissue between the fractions, while 
reoxygenation and cell cycle redistribution contribute to enhanced re-
sponsiveness of the tumor.2 In order to reduce treatment time and the 
number of irradiation sessions, hypofractionated settings with fewer frac-
tions of higher doses have been developed for cancer entities which ex-
hibit less pronounced differences in repair, regeneration, redistribution, 
and reoxygenation mechanisms compared to the surrounding normal tis-
sues. Here, patients receive fractions of more than 2.0 up to 6.0 Gy.9,10 
For breast cancer, this is already standard of care in the UK and parts of 
Canada.11,12 Finally, ablative RT regimens with high single doses of 15 Gy 
and more are clinically implemented in stereotactic protocols and in intra-
operative settings (IORT) where the dose is administered directly into the 
former tumor bed during surgery prior to wound closure. IORT is com-
monly used for the treatment of sarcoma, breast, pancreas, and colon 
cancer.13–16
Except for whole body irradiation as conditioning step for bone mar-
row and stem cell transplantation in case of leukemia treatment, the vast 
majority of tumor lesions are irradiated locally. Nevertheless, distant and 
systemic effects have been observed. One of the first clinical reports in 
this regard dates back to 1908, when H.D. McCulloch irradiated ‘lym-
phatic glands’ remote from the tumor lesion and subsequently observed 
distant tumor regression 17 (Figure 1). However, it should be mentioned 
that this report lacks an exact description of the irradiation procedure, the 
irradiation dose, and the localization of the irradiated ‘lymphatic glands’. 
Accordingly, side effects, including scatter radiation, cannot be decisively 
ruled out. In 1938, G. Segal and C.- P. Leblond reported that IR can pro-
voke effects in organs outside the irradiated field.18 Upon irradiation of 
the abdomen of rats with 20- 40 Gy, they observed ‘une réaction non 
spécifique’ in the shielded, non- irradiated parts of the animals as char-
acterized by atrophy of the lymphoid organs and hypertrophy of the ad-
renal glands. Interestingly, this effect was abolished upon removal of the 
adrenal glands, thus excluding the possibility of ineffective shielding. In 
1953, R.H. Mole introduced the term ‘abscopal effects’ (lat.: ab = away, 
scopus = target) to describe radiation effects ‘at a distance from the 
F IGURE  1 Selected milestone publications in the history of radiotherapy- induced abscopal effects [Colour figure can be viewed at 
wileyonlinelibrary.com]
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irradiated volume but within the same organism’.19 Although originally 
not coined in a tumor context, nowadays the phrase is commonly used 
in terms of anti- tumor activity seen outside the irradiation field. The clini-
cal relevance of RT- mediated abscopal effects has long been questioned, 
since it remained limited to sporadic clinical case reports. However, with 
the development of novel immunotherapeutic agents, including check-
point blockers such as Ipilimumab, abscopal effects are being increasingly 
observed, and efforts to make them clinically exploitable are on the rise.
3  | SYSTEMIC ACTIVATION OF THE  
IMMUNE SYSTEM BY LOCAL  
RADIOTHERAPY
Albeit an involvement of the immune system in tumor control was pos-
tulated already a long time ago by P. Ehrlich,20 it took more than 50 years 
after Mole’s report until S. Demaria and S.C. Formenti expressed in 
2004 that abscopal effects induced by IR are immune- mediated 21 
(Figure 1). They confirmed earlier reports which had already suggested 
a contribution of the immune system,22–31 and they were the first to 
explicitly draw this conclusion. Today, we know that the immune system 
represents the missing link between local RT and systemic abscopal ef-
fects, since RT is able to stimulate distinct forms of cell death that are 
recognized by the immune system as dangerous.32–34 The awareness 
that apart from its anti- proliferative capacity, the induction of effective 
anti- tumor immunity contributes to the therapeutic outcome of RT may 
shift the focus of interest of clinicians and basic scientists in future.
Historically, RT was considered to have immunosuppressive effects 
and to enforce immunological tolerance. One reason for this might be that 
lymphocytes are among the most radiosensitive cells within the body.35 
IR reportedly can lead to lymphocytopenia,36 although direct cytotoxic 
effects of RT are unlikely to account for this phenomenon, since systemic 
lymphocytopenia was observed upon local RT, and it persisted for sev-
eral months.37 RT can also induce the downregulation of the costimula-
tory surface markers CD80 and CD86 on immature dendritic cells (DCs) 
thus hampering T- cell activation.38 Nonetheless, there is accumulating 
evidence that RT is able to stimulate activating immune responses, and—
in contrast—might help to reverse the tolerogenic phenotype of many 
tumors. In response to RT, cells undergo different forms of cell death 
and/or cell stress. Depending on the irradiation dose, the cellular origin, 
the genetic repertoire, and the functionality of cell cycle checkpoints, 
diverse phenotypes of apoptosis, necrosis, mitotic catastrophe, and/
or senescence can be observed as has been reviewed elsewhere.33,39 
Notably, the different cell death modalities clearly vary in their immu-
nogenic potential. In order to trigger productive anti- tumor immune re-
sponses, it is generally accepted that tumor cells need to undergo forms 
of cell death which are sensed by the immune system as dangerous and 
which are accompanied by the exposure and release of danger signals 
and damage- associated molecular patterns (DAMPs) that attract and 
activate cells of the innate as well as the adaptive immune system.5,40 
Briefly, DAMP release triggers extravasation of monocytes and pro-
motes DC maturation and activation. Activated DCs present and cross- 
present tumor antigens to naïve T cells, thus priming the establishment 
of adaptive, anti- tumor responses, which per se are able to counteract 
the irradiated tumor as well as distant, out- of- field metastases (Figure 2). 
Mechanistically, an intratumoral cascade of type I and type II interferons 
(IFNs) is of essential importance in this scenario. Upon phagocytosis of 
dying irradiated tumor cells, tumor- derived DNA fragments enter the cy-
tosol of DCs and activate the cytosolic DNA sensor cGAS finally leading 
to STING- mediated transcription of type I IFNs (IFNα and/or IFNβ).41,42 
Since cGAS in principle can sense any DNA that enters the cytosol,43 
RT- induced accumulation of cytosolic DNA fragments might also induce 
intrinsic type I IFN production in irradiated tumor cells. Irrespective of 
their cellular origin, type I IFNs stimulate antigen cross- presentation by 
DCs, enhanced T- cell priming in the lymph nodes, and thus the formation 
of irradiation- induced tumor- specific T- cell responses.41,44,45 Activated T 
cells and natural killer cells (NK cells), in turn, secrete type II interferons 
(IFNγ) which enhance major histocompatibility complex (MHC) class I ex-
pression on tumor cells ultimately resulting in increased immune recogni-
tion.46 Moreover, IFNγ was shown to modulate the tumor vasculature for 
improved T- cell trafficking,46 and type I IFNs enhance T- cell recruitment 
by stimulating chemokine secretion.47 Most importantly, the treatment 
efficacy of RT in tumor- bearing immunocompetent mice was abrogated 
in the absence of type I IFN signaling.41
According to the classical concept of tumor immunoediting, estab-
lished tumors have evolved mechanisms to avoid immune destruction.48 
This commonly results in a strongly immunosuppressive microenviron-
ment and a tolerogenic phenotype of tumors. IR is able to shift this 
immunosuppressive microenvironment toward being more immuno-
supportive.49 Via the described IFN cascade, IR enforces the presenta-
tion of an extended MHCI ligandome on tumor cells and supports the 
recruitment, activation, and function of DCs and T cells.41,44,50,51 This 
resembles a defense response upon viral infection, and it is feasible to 
assume that cytosolic DNA fragments generated upon IR can act as viral 
mimetics in this regard. Along these lines, IR meanwhile is considered as 
a means of in situ cancer vaccination by turning the tumor into an ‘im-
munogenic hub’ 52 (Figure 2). In principle, irradiated tumor cells provide 
all compounds needed for a classic vaccination approach: tumor- specific 
antigens and adjuvants represented by DAMPs exposed and released 
upon IR. However, whether IR alone is able to stimulate long- lasting 
immunological memory as it is a prerequisite for successful vaccination 
remains questionable. Still, the stimulation of systemic abscopal effects 
by local RT and their persistence for several months endorses the idea 
of—at least short- term—established anti- tumor immunity.53
4  | STUDIES OF IRRADIATION- INDUCED 
ANTI- TUMOR IMMUNITY AND ABSCOPAL 
EFFECTS IN PRECLINICAL ANIMAL MODELS
Our knowledge about RT- induced anti- tumor immune mechanisms 
and resulting abscopal effects is largely based on preclinical model sys-
tems. In order to analyze the extent and the molecular determinants of 
immune- mediated, abscopal growth inhibition and tumor rejection, re-
searchers have established and utilized a set of tumor model systems 
which are discussed in this section (Table 1, Figure 3). Importantly, 
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none of these models per se can be considered as undisputedly su-
perior to any of the others; they rather differ with regard to their 
depth in information and exhibit unique advantages and limitations. 
In principle, preclinical research in oncoimmunology employs not only 
transplantation models but also autochthonous models which include 
genetically engineered and carcinogen- induced tumors.54,55 Although 
representing tumors whose development is more realistic than that of 
transplantable tumors, the latter two are clearly underrepresented in 
experimental reports studying RT- induced anti- tumor effects, whereas 
heterotopic transplantation models such as subcutaneous flank, 
F IGURE  3 Different experimental 
model systems that are commonly 
employed to study RT- mediated abscopal 
effects. Icons correspond to Table 1. 
For detailed information, please see 
text [Colour figure can be viewed at 
wileyonlinelibrary.com]
F IGURE  2 Schematic of radiotherapy- induced abscopal effects and out- of- field lesion regression. In this example, the primary tumor 
was removed by surgery, and abscopal anti- tumor immunity was induced by RT of a pulmonary metastasis combined with systemic immune 
checkpoint blockade. The generation of an in situ vaccine by RT and immune checkpoint blockade is depicted in the right part of the scheme: 
Tumor antigens together with adjuvant DAMPs are released by dying tumor cells and are taken up and processed by DCs which in turn (cross- )
present these tumor antigens to naïve T cells in a tumor- draining lymph node. Systemic anti- tumor immunity is achieved by activated T cells 
which leave the lymph node and subsequently attack metastatic tumor nodules at distant, non- irradiated sites [Colour figure can be viewed at 
wileyonlinelibrary.com]
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footpad, or thigh tumors, are used in the majority of cases. The main 
reason for the frequent use of transplantable, subcutaneous tumors is 
that these are easily generated and their monitoring is readily achiev-
able in comparison to most orthotopic tumors which grow within 
the body and thus require modern imaging techniques and equip-
ment. Moreover, external beam RT can be easily delivered to subcu-
taneous tumors with concurrent minimal damage to non- cancerous 
surrounding tissue. This was particularly important in earlier studies 
where proper dose distribution and protective shielding were often 
realized by simply using lead plates or boxes in order to expose the 
small tumor- bearing regions of the animals’ bodies.18,56 Within the last 
years, the development of highly sophisticated small animal irradia-
tion platforms has overcome this difficulty: Image- guided RT planning 
now closely mimics the clinical situation and therefore allows irradia-
tion of orthotopically transplanted tumors at virtually any location in 
the body without excessive irradiation of non- malignant tissue and 
organs at risk.57–59 In principle, these small animal RT devices could 
also be used for the treatment of autochthonous malignancies such 
as spontaneously occurring and carcinogen- induced tumors. However, 
standardized RT of these tumors requires extensive monitoring, since 
the exact location and onset of tumor growth cannot be precisely pre-
dicted. Besides, tumor growth at multiple sites is frequent, thus ren-
dering treatment planning even more complex.
5  | PRECLINICAL MODEL SYSTEMS 
EMPLOYED TO EXPLORE SYSTEMIC, 
ABSCOPAL EFFECTS OF RADIOTHERAPY
5.1 | Focus on initial immune priming and 
subsequent immune effector functions: Analysis of 
immune mechanisms in the irradiated tumor itself
Many key mediators of irradiation- induced anti- tumor immunity 
such as the importance of type I interferon production mediated by 
STING,41,42,47 the essential role of tumor- specific IFNγ- producing T 
cells,44,46,60 and the contribution of DCs cross- presenting tumor anti-
gens,41 were identified in transplantable tumor models using a single 
tumor that is irradiated. To this end, a suspension of tumor cells cultured 
in vitro or obtained from a tumor- bearing donor animal is injected sub-
cutaneously. After tumor engraftment (usually 1- 3 weeks), tumor RT is 
performed. Any immunomodulatory substance or combinations thereof 
can be applied in basically every arbitrary sequence: before, during, or 
after irradiation. Readout endpoints comprise tumor growth, survival, 
intratumoral, and/or systemic immune parameters (Figure 3, 1st panel).
5.2 | Focus on long- lasting systemic effects: Tumor 
rechallenge in treated animals or in naïve animals after 
bone marrow transplantation or adoptive T- cell transfer
Tumor rechallenge experiments are used to test long- lasting, sys-
temic, immune- mediated protection against a formerly rejected 
tumor. Animals whose tumors have been treated are rechallenged 
by a second injection of tumor cells which is also rejected if suf-
ficient anti- tumor immunity has been achieved. In order to demon-
strate tumor specificity of this immune response, failure to reject 
another, antigenetically unrelated tumor can be demonstrated si-
multaneously. Instead of rechallenging a treated animal, it is also 
possible to investigate whether the suggested systemic immunity 
of a treated animal can be transferred to another, naïve animal by 
transplanting splenocytes and/or bone marrow cells or by adop-
tively transferring mature T cells from the donor prior to tumor 
inoculation in the recipient.28,49 To thoroughly exclude that donor- 
independent immunity is induced in the recipient, these animals’ 
immune cells can be depleted a priori by a sublethal dose of whole 
body IR before bone marrow/stem cell transplantation, or adoptive 
transfer, respectively 49 (Figure 3, 2nd panel).
In case of full protective immunity, all rechallenged mice dis-
play long- term survival. In several cases, tumor regression in only a 
fraction of the tested animals is observed, and this is dependent on 
the amount of tumor cells injected.49,61 Moreover, immunity against 
tumor rechallenge after successful RT might suggest but not guaran-
tee that truly abscopal tumor regression can be demonstrated in the 
same model system. For instance, Filatenkov et al.49 excluded the 
possibility of IR- induced abscopal effects in a murine colon carci-
noma model, because systemic immunity was not achieved immedi-
ately but rather weeks after RT. Besides, it is very important to stress 
that the test for immunological memory only reflects the host’s ca-
pacity to reject a tumor at a certain time point of rechallenge. Pioneer 
works at the beginning of the 20th century already demonstrated 
that immune- mediated tumor rejection may gradually decline within 
weeks.62 Another study found that the probability of tumor rejection 
is not only dependent on the time span between generation of anti- 
tumor immunity and rechallenge but may also be heavily diminished 
if a preexisting large tumor mass is still present in the organism 61 
—a situation which is frequently observed when treating cancer pa-
tients with late- stage disease. Additionally, it should be noted that 
the capacity to reject a subcutaneous tumor rechallenge does not 
necessarily predict that the entire body displays a similarly high de-
gree of immunologic memory irrespective of the site of rechallenge. 
This phenomenon is known from pathogen vaccination studies 63 
and is further supported by the fact that tissue- specific peculiarities 
of the immune system are well- known.64 Hence, successful rejection 
of a tumor rechallenge at a certain time point and in a certain tissue 
is a very important indicator of anti- tumor immunity in preclinical 
model systems, but it does not always predict temporally unlimited 
and truly systemic anti- tumor immunity.
5.3 | Focus on abscopal effects on out- of field 
lesions: Model systems with secondary tumors and/or 
systemic tumor cell injection
The prototypical model system to study abscopal effects of RT is an 
animal with two subcutaneous tumors that are inoculated into both 
the left and the right flank or hindleg, and only one of the two tumors 
is irradiated (while scattered IR to the second tumor must strictly be 
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excluded). In case of an abscopal response, growth delay of the non- 
irradiated tumor or even total regression is observed (Figure 3, 3rd 
panel).
In a variation of this experimental setup, the secondary tumor in-
jection is applied intravenously or into the spleen resulting in multi-
ple disseminated tumor nodules in a specific organ such as the lungs 
or the liver.29,31,65–69 The most common readout endpoint in this 
setting is the quantification of tumor growth in the non- irradiated 
organ—either by enumeration or by simply determining the weight 
of the tumor- infiltrated organ.28,29,31,57,65,68–70 In case of an abscopal 
response, the extent of tumor growth in the non- irradiated organ is 
markedly decreased. Occasionally, this model system is also employed 
to determine abscopal effects on artificial ‘metastases’ generated 
via disseminated distribution of intravenously injected tumor cells. 
However, it should be noted that the tumor cells in this setting do not 
originate from a primary tumor but rather were artificially introduced 
by systemic injection. Hence, these ‘metastases’ might exhibit larger 
genetic and thus antigenic similarity to the primary tumor than gen-
uine metastases do.71–73 Therefore, it remains questionable whether 
an inhibition of bona fide metastasis in a (pre- )clinical situation can be 
deduced from results obtained in this model.
Another variant of this model uses only a single intravenous in-
jection of tumor cells which subsequently form nodules in a certain 
organ of interest such as lung or liver.22,23 Upon application of IR to 
one half of the infiltrated organ, the number of tumor nodules in the 
non- irradiated part of the same organ can be assessed as described 
above. However, the risk of unintentionally irradiating the abscopal 
field in this setting is higher than in those situations where the two 
tumor lesions are separated more clearly or with a delay in time.
5.4 | Focus on abscopal effects on distant  
metastases: Model systems with autochthonous  
metastases
Some tumor cell lines such as the murine mammary carcinoma 4T1 
and Lewis lung carcinoma cells, spontaneously metastasize to dis-
tant organs even after subcutaneous implantation.24,26,30,74–80 This 
property can be exploited to measure abscopal effects on metastatic 
growth after IR of the primary tumor (Figure 3, 4th panel). The se-
verity of the metastatic process is eventually quantified as described 
above. In contrast to model systems using ‘experimental metastases’ 
introduced by intravenous or intrasplenic injection of tumor cells, this 
setup allows to study the abscopal inhibition of bona fide metastases 
after RT and thus also accounts for the fact that metastatic lesions 
might already have acquired different antigenic properties, thus dis-
tinguishing them from their tumor of origin.71–73
Importantly, to ascertain the detection of abscopal effects on 
distant metastases (instead of the primary tumor’s incapacity to give 
rise to metastatic cells), therapy of the primary tumor needs to be 
started at a time point when micrometastases have already formed 
in the respective organ. However, since this experimental detail is not 
considered by all authors whose work is discussed here, it cannot be 
excluded that some of them merely detected anti- tumor effects on the 
primary tumor prior to dissemination instead of truly abscopal effects 
on existing metastases.
6  | ENHANCEMENT OF RADIOTHERAPY- 
INDUCED ANTI- TUMOR IMMUNITY: 
IMMUNOMODULATORS, CHEMOTHERAPY, 
AND EXOGENOUS TUMOR CELL VACCINES
Even before 2004, when Demaria et al.21 identified the immune sys-
tem as the key mediator of abscopal anti- tumor effects, researchers in 
this field had already focused on combining RT with immunomodula-
tion in order to strengthen the immune response against out- of- field 
and/or metastatic tumor lesions of various origins.22–31,80 Since then, 
a plethora of—in the broadest sense—immunomodulatory substances 
has been tested for their capacity to strengthen systemic anti- tumor 
immune responses or to unleash abscopal effects in the first place. 
Despite their heterogeneity, the majority of these substances can be 
summarized into groups which share common properties.
Earlier in vivo studies on RT- induced anti- tumor immunity and ab-
scopal effects frequently tested the co- administration of cytokines. 
By the 1980s, the T- cell proliferation stimulating activity of inter-
leukin (IL)- 2 had already been demonstrated in preclinical and clini-
cal cancer immunotherapy,81,82 and this cytokine was consequently 
used in preclinical studies to explore its synergy with RT in murine 
models of melanoma, lymphoma, colorectal, mammary, and renal cell 
carcinoma.22,23,25,27,28,69 In order to reduce the severe side effects of 
systemic IL- 2 application, peri- or intratumoral administration was suc-
cessfully employed.25,27,28,69 Apart from IL- 2, other mostly proinflam-
matory cytokines were combined with RT, including the DC- stimulating 
Fms- like tyrosine kinase receptor 3 ligand (Flt3- L),21,24,83,84 IL- 12 alone 
or in combination with Granulocyte macrophage colony- stimulating 
factor (GM- CSF) or M- CSF, respectively.26,30,68 Furthermore, M- CSF 
alone and the Macrophage inflammatory protein 1α variant ECI301 
were successfully tested for their combination with RT.80,85,86 Hence, 
the capacity of certain cytokines to induce either T- cell proliferation 
and/or activation of antigen- presenting cells (APCs) necessary for T- 
cell priming apparently can be exploited to enhance RT- induced anti- 
tumor immunity and thus abscopal effects in animal models.
The transfer of immune cells is another treatment option to enforce 
RT- induced anti- tumor immunity which can additionally be combined 
with cytokine administration. For instance, in vitro differentiated DCs 
were successfully used to improve anti- tumor immunity in sarcoma and 
for abscopal regression of non- irradiated lung tumors induced by sys-
temic injection of melanoma cells.28,87 Analogously, injections of T cells 
potentiated anti- tumor immunity when combined with RT, thus induc-
ing abscopal effects in lymphoma and in experimental liver metastases 
induced by intrasplenic injection of colorectal cancer cells.23,45
Whereas the rationale for cytokine administration and/or injection 
of immune cells derives from the fact that subsequent immune ac-
tivation can induce tumor regression, a complementary approach of 
attenuating immunosuppression and reinvigorating T- cell responses 
against growing tumors has been underestimated for decades and 
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gained enormous attention within the last years. Without knowing 
the importance of T cells in anti- tumor immunity at that time, early 
works by J. Vaage61 already demonstrated that the host’s capacity to 
establish anti- tumor immunity gradually declines if the size of a tumor 
exceeds a certain threshold. Indeed, as demonstrated in later works, 
evolving tumors gradually establish an immunosuppressive microen-
vironment which is infiltrated by regulatory T cells (Tregs), alterna-
tively activated macrophages and myeloid- derived suppressor cells 
(MDSCs).88,89 To overcome this immune inhibition, monoclonal anti-
bodies have shown remarkable anti- tumor efficacy in both preclinical 
and clinical situations. The most well- known example of these immune 
checkpoint inhibitors is the antagonistic antibody against cytotoxic T- 
lymphocyte- associated protein 4 (CTLA- 4). Its target is expressed on T 
cells and binds to the ligand B7- 1 on APCs, thus preventing T- cell ac-
tivation.90,91 The capacity of CTLA- 4- blocking antibodies to reactivate 
T cells and therefore inhibit tumor growth was demonstrated more 
than 20 years ago,92 and Ipilimumab—one of the human anti- CTLA- 4 
antibodies—was the first immune checkpoint blocking antibody in 
cancer therapy which was approved by the FDA and the European 
Commission for the treatment of unresectable melanoma in 2011 
(Figure 1). Considering its clinical efficacy in melanoma,93 it is not 
surprising that anti- CTLA- 4 is also the most often used substance to 
demonstrate T cell- dependent abscopal effects in preclinical settings. 
Various authors observed metastasis inhibition, abscopal regression 
of secondary tumors, and establishment of immunological memory 
in tumor rechallenge experiments upon combination of RT with anti- 
CTLA- 4 treatment.65,77,79,94–97 These findings are not restricted to 
a certain mouse model but rather underline the versatile efficacy of 
CTLA- 4 blockade in various cancer entities: Abscopal effects were ob-
served in mammary and colorectal tumors, melanoma, and mesothe-
lioma. Nevertheless, disadvantages of this therapeutic regimen also 
became apparent. Severe multiorgan autoimmune pathologies were 
observed in the treated animals which closely resemble the immune- 
related adverse effects of Ipilimumab treatment in the clinic.65,98,99
Another study concentrated on the issue that RT in combination 
with CTLA- 4 blockade, albeit being effective in some patients, is un-
able to induce enduring anti- tumor immunity in the majority of cases 
both in preclinical and clinical settings. The authors attributed this to 
therapy- induced expression of programmed death ligand 1 (PD- L1) 
on tumor cells.97 Indeed, the axis of PD- L1 and its cognate receptor 
programmed death 1 (PD- 1) on the surface of T cells is known as 
another T- cell inhibiting signaling pathway. Similarly to anti- CTLA- 4 
treatment, inhibition of the PD- 1/PD- L1 immune checkpoint en-
hances the activation of T cells, thus facilitating T cell- dependent anti- 
tumor immunity.100,101 However, whereas CTLA- 4 blockade results in 
a broad systemic activation of T cells explaining strong immune cell 
infiltration and immunopathology in non- malignant tissue,65,102 T- cell 
activation by blockade of PD- 1 or PD- L1 appears to be more subtle. 
Since PD- 1 expression is induced on exhausted T cells frequently 
found within the immunosuppressive milieu of tumors, antibodies 
targeting the PD- 1/PD- L1- axis not surprisingly proved to be effec-
tive immunomodulating anti- cancer agents both in preclinical mod-
els and in the clinic.100,101,103,104 The combination of anti- PD- L1 or 
anti- PD- 1 antibodies with RT evoked abscopal tumor regression in 
murine melanoma and in mammary, renal, and colon carcinoma mod-
els.65,74,76,88,94,97,105 Interestingly, studies using a triple therapy with RT 
and simultaneous blockade of the PD- 1/PD- L1- axis as well as CTLA- 4 
showed conflicting results with regard to the additional effect of com-
bined immune checkpoint blockade on abscopal tumor responses.94,97 
Apart from interfering with CTLA- 4 and PD1/PD- L1 function, a few 
preclinical studies employed other monoclonal antibodies combined 
with RT in order to increase anti- tumor immunity. For instance, RT in 
combination with T cell- activating antibodies against 4- 1BB (CD137) 
plus PD- 1 blockade induced abscopal effects in melanoma, breast, 
and colon tumors.76 Moreover, abscopal regression in three differ-
ent murine breast cancer models upon RT together with blockade 
of transforming growth factor- β (TGF- β) or Her2/neu was demon-
strated.74,75 Unlike anti- CTLA- 4, anti- PD- 1, and anti- PD- L1, these an-
tibodies are not considered as classical immune checkpoint inhibitors. 
Nevertheless, their use in combination with RT showed encouraging 
results and renders them interesting tools for further investigation.
Importantly, various other immunomodulatory substances have 
been reported to induce systemic anti- tumor immunity when com-
bined with RT. Abscopal responses were observed with aptamers 
targeting 4- 1BB (CD137) and/or vascular endothelial growth factor 
(VEGF), as well as with agonists for Toll- like receptor (TLR)- 7 or TLR- 
9, respectively.65,78,106 Combination of RT with gene therapeutic ap-
proaches using IFNβ- producing DCs, T cell- activating viral vaccines 
or cytokine- expressing tumor cells improved systemic immunity and 
induced abscopal effects in various tumor models.70,107–111 Two other 
studies combined RT with herpes simplex virus thymidine kinase (HSV- 
tk)- based suicide gene therapy and systemic ganciclovir administration 
leading to abscopal effects.29,31
The aim of combining local RT with any type of immunomodulatory 
substance as discussed above is to enhance and improve the in situ 
cancer vaccination effects of RT (Figure 2). Along these lines, several 
preclinical studies also tested exogenous tumor vaccination procedures 
in order to stimulate systemic anti- tumor immunity.49,61,84,96,108,109,112 
Interestingly, the vaccination effect of ex vivo- irradiated tumor cells 
(mixed with varying adjuvants) was rather weak, and in some reports 
it was even counterproductive with regard to different endpoints, in-
cluding rejection of a tumor challenge and regression of an abscopal 
tumor upon RT,49,96,109,112 whereas evidence for much more potent 
anti- tumor immunity was observed if the irradiated tumor cell vaccine 
was genetically modified to produce either GM- CSF alone or GM- CSF, 
IL- 2, and IFNγ.108
Last but not least, some authors also tested different chemothera-
peutics in combination with RT and analyzed their impact on abscopal 
tumor regression.86,110,128 It is well- known that the induction of can-
cer cell death by distinct chemotherapeutics such as anthracyclines, 
cyclophosphamide, and oxaliplatin can activate strong anti- tumor im-
mune responses, whereas other substances like mitomycin C fail to 
do so.3,113–117 Notably, we were unable to find a study which utilized 
any chemotherapeutic agent in order to enhance the abscopal effects 
of RT in fully immunocompetent animals. Instead, one group reported 
that abscopal effects on lung metastases were nearly completely 
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abolished upon combination of RT with paclitaxel in murine mammary 
carcinoma.110 Since combinations of RT and various chemothera-
peutics are extensively used in the clinical routine, their potential to 
activate anti- tumor immunity and abscopal effects should be further 
investigated in preclinical model systems which mimic the clinical situ-
ation as closely as possible.
7  | CRITICAL PARAMETERS OF SYSTEMIC 
ANTI- TUMOR REACTIONS AND ABSCOPAL 
EFFECTS INDUCED BY RADIOTHERAPY
7.1 | Timing and dosing of radiotherapy and 
additional therapeutics
So far, we have not paid attention to the dose of IR which was ap-
plied to the tumor in order to induce anti- tumor immunity. However, 
although desirable, it is not possible to extrapolate an ‘optimal’ RT 
scheme for the induction of abscopal effects. Only few researchers 
compared different irradiation regimens in their studies on out- of- 
field tumor regression and tested various RT schemes such as classi-
cally fractionated (2 Gy daily), hypofractionated (between 2 and 10 Gy 
per	dose),	and	high	single	dose	(i.e.	ablative,	≥15	Gy)	irradiation	strat-
egies.21,22,30,61,95,105,118 Fractionated and hypofractionated IR elicited 
potent anti- tumor immune responses in mouse models of melanoma, 
lymphoma, breast, colon, and lung carcinoma,25,27,30,69,105,119 and even 
brachytherapy (a technique where a radiation source is implanted into 
the tumor for continuous IR delivery with low dose rates) was suc-
cessfully used in one study.70 In contrast, other groups reported that 
anti-	tumor	immunity	induced	by	ablative	doses	of	≥15	Gy	was	more	
potent than after fractionated treatments in murine melanoma and 
colon carcinoma,44,49 whereas Dewan et al.95 found that hypofrac-
tionation (3×8 Gy) was superior both to a single dose of 20 Gy and a 
regimen using more and smaller fractions (5×6 Gy). In part, these re-
sults are conflicting, but it needs to be mentioned that the terms ‘high- 
dose’, ‘low- dose’, ‘fractionated’, and ‘hypofractionated’ RT are used 
inconsistently in preclinical reports, thus leading to misinterpretations 
when comparing studies from different researchers. Nevertheless, it 
is remarkable that the majority of all studies discussed here employed 
(high) single- dose IR or hypofractionated regimens with relatively 
large	doses	(≥6	Gy)	to	induce	abscopal	effects.
Apart from the efficacy of RT itself, the capacity of combined 
treatment approaches to synergize with IR may also have substantial 
impact on the therapeutic outcome: As discussed above, most studies 
demonstrated an enhanced therapeutic effect of RT when combined 
with additional therapeutics, whereas RT alone was either ineffective 
or inferior to the combined modality approaches tested. However, 
this is further complicated by the fact that not only timing and con-
centration of additional therapeutics but also their site of application 
may largely influence the establishment of anti- tumor immunity. For 
instance, abscopal tumor regression upon RT plus IL- 2 administra-
tion was reported for systemic, peritumoral, or intratumoral IL- 2 ap-
plication, respectively, making it even more complex to identify the 
best- suited therapy.22,25,27,69 However, even large- scale experiments 
with dozens of treatment groups evaluating the injection of an im-
munomodulatory substance at various time points and concentrations 
only have limited informative value.30 Hence, efficacious combinato-
rial treatment approaches in preclinical models need to be carefully 
elaborated in order to prevent that unsuitable timing and dosing will 
disqualify a potentially useful therapeutic combination.
7.2 | Mediators of systemic, abscopal anti- tumor  
effects
Considering the work of various authors, there is clear evidence that 
RT- induced systemic immune responses and abscopal effects largely 
depend on T cells. This was demonstrated in numerous studies using T- 
cell depletion experiments.22,42,45,49,58–60,74,76,77,79,86,88,94,97,106,110,120 
However, conflicting data were published on the contribution of CD4+ 
T cells, which were either important, dispensable, or even inhibitory 
in this context, respectively.22,49,59,74,76,77,79,86,88,94,106 Besides, sev-
eral authors analyzed the antigen specificity of the relevant T- cell re-
sponses by employing animal tumors which express model antigens 
such as ovalbumin (OVA) or SIYRYYGL—a peptide epitope derived 
thereof.44,45,76,110,119 On the one hand, these studies clearly demon-
strated that RT (combined with other treatments) is able to induce 
tumor antigen- specific T cells which react to an antigen only expressed 
on cancer cells. On the other hand, the presence of foreign antigens 
in a tumor will increase its immunogenicity and thus artificially sim-
plify tumor rejection unless the same antigen is also introduced into in 
the host. This holds also true for the transduction of reporter genes, 
including luciferase and green fluorescence protein (GFP) which facili-
tate in vivo detection of tumor cells but also represent immunogenic 
antigens for the host’s immune system.121,122
Two recent studies have overcome this drawback of model 
antigen- expressing tumors by in- depth analyses of clonal T- cell ex-
pansion: Using immunosequencing of the T- cell receptor repertoire, 
both reports revealed that RT is able to increase the intratumoral T- 
cell receptor diversity in melanoma and colon cancer models.97,105 
Interestingly, the two studies employed completely different RT regi-
mens (1×20 Gy vs 5×2 Gy), thus proving that T- cell expansion after RT 
is not restricted to a specific irradiation regimen. Furthermore, Dovedi 
et al. not only analyzed T- cell clonality in irradiated but also in abscopal 
lesions. In their study, fractionated RT, albeit inducing a polyclonal T- 
cell response in the irradiated tumor, was unable to diversify the T- cell 
receptor repertoire at the abscopal site. Importantly, the limited sys-
temic effects of fractionated RT on T- cell expansion were overcome by 
additional PD- 1 blockade leading to strong diversification of the ex-
panded T- cell clones at both tumor sites. This was paralleled by higher 
complete regression rates of non- irradiated tumors as compared to 
abscopal tumors in animals receiving RT alone.105 The results further 
suggested that hypofractionated or ablative RT in combination with 
PD- 1 blockade might even be more potent in this regard—an issue that 
needs to be addressed in greater detail. Nevertheless, the two stud-
ies clearly underline the importance of clonal intratumoral T- cell ex-
pansion, and it is evident that further studies with focus on the T- cell 
receptor repertoire will improve our understanding of T cell- mediated 
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abscopal tumor regression. Yet, it needs to be mentioned that the in-
duction of T- cell responses alone is not always predictive of potent 
anti- tumor immunity. For instance, recruitment of immune cells, in-
cluding T cells, into tumors may be abrogated by a process termed 
endothelial cell anergy. This inactivation of the tumor endothelium is 
characterized by downregulation of Intercellular Adhesion Molecule- 1 
(ICAM- 1) 123,124 and can be overcome by local low- dose (2 Gy) IR 
leading to activation of inducible NO synthase (iNOS) expressing mac-
rophages.125 However, in other settings, endothelial cell anergy may 
inhibit potent anti- tumor immune responses even in the presence of 
tumor- specific T cells.
A few studies also suggested that not exclusively T cells and 
their effective priming by DCs but also other factors contribute to 
abscopal anti- tumor responses. For example, an involvement of NK 
cells and a negative regulation by intratumoral MDSCs have been 
proposed,30,49,68,86,126 whereas B cells appear to be dispensable.78,83 
Furthermore, two groups reported on the tumor suppressor protein 
p53 as a mediator of RT- stimulated abscopal effects. Murine lung tu-
mors and fibrosarcomas regressed upon excessive irradiation of distant 
healthy tissue in wildtype but not in p53 mutant mice.127 The mecha-
nisms underlying this effect were not further dissected, but an involve-
ment of massive inflammatory cytokine production was proposed. 
Another study employed human colorectal xenografts with wildtype 
or p53 mutant tumors in nude mice, thus excluding any influence of 
T cells.118 Apart from this report, abscopal effects on human pancre-
atic xenograft tumors were also observed in T cell- deficient mice.128 
Although none of the two studies using nude mice clearly identified 
the major anti- tumoral effector(s), it may be speculated that NK cells 
exert inflammation- induced systemic anti- tumoral activity upon tumor 
RT—even or particularly if functional T cells are absent. Though, absco-
pal effects on human melanoma were also described upon combina-
tion of RT with injections of mesenchymal stem cells into NOD/SCID 
mice which are deficient in both B- , T- , and NK cells.129 Taken together, 
it can be concluded that the effects of RT on distant tumors are clearly 
but not exclusively T cell- dependent. The great majority of studies in 
this field either directly demonstrated the requirement of CD8+ and/
or CD4+ T cells, suggested their key player functions, or at least did not 
exclude a crucial role of T cells in mediating anti- tumor immunity and 
abscopal effects, respectively.
Finally, it is important to stress that, within the last two decades, 
most authors who detected abscopal tumor responses concentrated 
on their strength to inhibit distant tumor cell growth. Commonly, the 
efficacy to induce abscopal effects of RT alone was lower than in a 
combinatorial therapeutic setting. However, a few studies discussed 
here clearly showed or at least speculated on negative abscopal re-
sponses in tumor- bearing hosts, i.e. enhanced abscopal tumor growth 
compared to non- irradiated animals.69,118,128,130–132 Strikingly, the 
question whether local tumor irradiation might enhance or prevent 
abscopal metastasis growth (or the metastatic capacity of a tumor) was 
controversially discussed in recent times as reviewed by von Essen.133 
An early study by Kaplan and Murphy found an increase in pulmonary 
metastasis of subcutaneously implanted mammary carcinoma upon 
IR,132 and similar effects were described more than half a century later 
in a study by Camphausen et al.131 using lung and fibrosarcoma tu-
mors. At first sight, these reports appear to be in stark contrast to 
those of various other authors who showed a therapeutic benefit of 
primary tumor RT on distant metastasis. However, it is important to 
stress that both Kaplan and Murphy and Camphausen et al. started 
tumor RT treatment at a comparably late stage of tumor development 
when tumor diameters were in the range of 1 cm, whereas the vast 
majority of researchers who found anti- tumor abscopal effects ap-
plied RT as soon as tumors were palpable—i.e. at much earlier time 
points. Although it is impossible to reconstruct whether this fully ex-
plains metastasis- promoting abscopal effects described in historic ex-
periments, we hypothesize that the pioneers of preclinical tumor RT 
tended to initiate tumor RT at much later time points. Hence, negative 
abscopal effects of primary tumor RT in immunocompetent models 
may simply be considered as a confirmation of the aforementioned 
study by J. Vaage61 who stated that ‘immune resistance’ against mu-
rine tumors reaching 7- 8 mm diameter gradually declines with further 
tumor growth. Later on, Vaage et al.130 described that IR of the whole 
abdomen (most likely including the spleen) enhanced the growth of 
lung nodules after intravenous tumor cell injection. Similarly, another 
group demonstrated that RT of healthy tissue rather increased lung 
tumor growth of intravenously injected tumor cells.69 Finally, both of 
the studies that used nude mice showed moderate abscopal protumor 
effects of RT alone, although these effects were not tested for their 
statistical significance.118,134 Taken together, these results demon-
strate that not only the magnitude of abscopal anti- tumor effects but 
also the possibility of distant tumor growth promotion needs to be 
considered. Accordingly, the absence of any effect in a given setting 
may actually be the sum of two or more opposing abscopal phenom-
ena which—when assessing a certain readout endpoint such as tumor 
volume—unperceivably add up to zero. Besides, the studies in which 
normal tissue of immunocompetent animals was irradiated might 
suggest that applying IR to non- malignant tissue should not only be 
avoided in order to minimize healthy tissue damage but also to pre-
vent potential growth- promoting abscopal effects on distant tumor 
cells.69,130,135
8  | CLINICAL EXPERIENCES WITH 
ABSCOPAL EFFECTS OF RADIOTHERAPY
From a clinician’s perspective, abscopal effects appear unreal and 
promising at the same time. Phenomena like spontaneous tumor re-
gression and reduction of untreated tumor lesions following RT are 
indeed very rare, however, several case reports have been discussed 
in the literature and serve as a basis for new avenues in research as 
well as for the development of new treatment approaches.
Abscopal effects could be regarded as special variants of spon-
taneous tumor regression resulting from radiobiological influences. 
While in some early descriptions, the true existence of a malignant 
lesion that was treated remains questionable, later reports are more 
precise and are mostly confirmed by histological examinations.136 A 
systematic analysis of such cases published in the first half of the 20th 
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century shows—apart from a steady increase in the number of re-
ports—that some cancer entities seem to lead to spontaneous regres-
sion more frequently than others.136 Additionally, a trend concerning 
relevant trigger factors was determined and included immunological 
factors, irradiation, infection, and others.136 A potential relation-
ship between infection, cancer, and immune responses was already 
observed by W.B. Coley in 1893, when a patient having undergone 
several operations of his sarcoma showed a regressive response after 
an incidental erysipelas infection of his surgical wound.137 W.B. Coley 
could further confirm these observations and employed them to de-
velop an early immunotherapeutic approach by artificial injection of 
streptococci with imposing results: Several of his patients experienced 
improvements, and some were even cured of disease 137 (Figure 1).
Immense scientific advances meanwhile offer diverse options 
for the treatment of cancer today. Nevertheless, cancer therapy is 
still a challenge, and spontaneous regression remains an exceptional 
phenomenon. While abscopal effects of RT have repeatedly been re-
ported since the beginning of the 20th century, the number of case 
reports clearly increased with the introduction of immunomodulatory 
agents such as immune checkpoint inhibitors targeting CTLA- 4 and 
the PD- 1/PD- L1 axis.53 This suggests a close association between 
radiobiological and immunological mechanisms interacting in com-
plex ways and renders them highly promising with regard to therapy 
optimization.
9  | CASE REPORTS
Over the last decades, several case reports of RT- induced abscopal 
effects have been published. A systematic search of the respective 
literature reveals that sometimes the definition of abscopal effects 
is not restricted to out- of- field responses toward RT only but also 
to other types of therapy,138 whereas in other cases abscopal ef-
fects stimulated by RT are described as ‘spontaneous tumor regres-
sion’, thus rendering comprehensive analyses challenging.139–141 At 
first sight, the majority of patients with RT- induced abscopal effects 
are of advanced age, suffer from progressed and metastasized can-
cer, and are treated in palliative settings (Table 2). Although vari-
ous cancer entities can be found, some occur more frequently than 
others, particularly malignant melanoma, lymphoma, renal cell car-
cinoma (RCC), and hepatocellular carcinoma (HCC). Regarding prior 
therapies and preexisting conditions, the group of patients is highly 
heterogeneous.139,142–145 Some patients have undergone multiple dif-
ferent treatment approaches,146,147 and in other cases new additional 
therapies were started directly after the abscopal effects had been 
noticed.144,145 Follow- up times are commonly short, and causes of 
death are often not documented in detail.148,149 Most of the available 
case reports seem to reliably present RT- induced abscopal effects. 
Nevertheless, especially with such unusual and rare phenomena, a 
careful, well- structured and complete presentation is of primary im-
portance. Moreover, systematic analysis of the available reports is 
complicated by very heterogeneous depth in information, incoherent 
assessment criteria, missing time specifications and statistics, as well 
as hardly any patient and treatment details.145 Importantly, the ques-
tion about consistent documentation arises, as publications mostly 
are restricted to university hospitals, thus implying a bias for statisti-
cal analyses. This bias could even be aggravated by inhomogeneous 
availability of highly specialized imaging techniques as well as by their 
continuous technical improvement over time—in other words, lesions 
and their dynamics which might be imaged easily today would not 
have been detected a few decades ago.
Despite the above mentioned difficulties and limitations of pub-
lished case reports, attempts to systematically analyze RT- related 
abscopal effects have been undertaken and allow insights into the fre-
quencies and the groups of patients who displayed abscopal effects, 
even if they may not entirely present all cases published. Reynders 
et al. accurately analyzed 23 case reports and one retrospective study 
conforming with well- defined research criteria and calculated a me-
dian age of 64.5 years and a median total irradiation dose of 32 Gy 
(12- 60.75 Gy) at single doses between 1.2- 26 Gy.53 The primary 
tumor was irradiated in eight patients, whereas metastases or lymph 
nodes constituted the irradiated volume in 15 cases. Abscopal re-
sponses occurred after less than 1- 24 months persisting for a median 
time of 5 months, and relapse- free follow- up lasted for a median time 
of 13 months, but could not be determined in all cases.53 This study 
shows that—although reports are heterogeneous—some common fea-
tures, including age, tumor stage, and predominating cancer entities 
can be extracted and should be investigated in greater detail with view 
to, but independent of preclinical results, in order to develop improved 
treatment strategies and to evaluate the transferability of preclinical 
results into clinical application.
10  | MECHANISTIC CONSIDERATIONS
The therapeutic accessibility of tumor cells is one major challenge 
in cancer treatment, especially when trying to protect the normal 
healthy tissue. As described above, tumors evade immune control and 
hamper access and function of immune cells by various strategies. The 
mechanistic basis for RT- induced abscopal effects is a penetration 
and/or reversal of this immunosuppressive milieu, not only in the irra-
diated but also in distant lesions and maybe even systemically. Under 
certain conditions, RT is able to trigger these processes. However, the 
key factors such as irradiation dose, fractionation regimen, as well as 
size and localization of the irradiated lesion remain to be characterized 
in greater detail. Apparently, the clinical implementation of immune 
checkpoint blockers has rendered case reports with RT- induced ab-
scopal effects more frequent suggesting a high degree of synergism 
between RT and immune checkpoint inhibition.53
10.1 | Immune checkpoint blockade in clinical use: 
Some limitations when applied as monotherapy
Immune checkpoint blocking antibodies targeting CTLA- 4 or the 
PD- 1/PD- L1- axis can unleash endogenous anti- tumor immune re-
sponses with impressive results. Accordingly, clinical approval was 
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granted for several cancer entities, including metastatic melanoma, 
RCC, non- small cell lung cancer (NSCLC), and others (Figure 1).
Although overall response rates of Ipilimumab monotherapy in 
metastatic melanoma are relatively low with approximately 11%, re-
sponding patients show clearly improved survival rates, and a sub-
group of long- term survivors has been described.93 Nevertheless, 
Ipilimumab treatment is often limited by severe toxic effects, includ-
ing rash, colitis, diarrhea, pruritus, dermatitis, uveitis, nephritis, and 
hepatitis—synoptically (auto- )immune- related symptoms which can 
be life- threatening in the worst case.150,151 In order to counteract 
these adverse effects, immunosuppressive agents such as steroids, 
Infliximab and Mycophenolate mofetil are applied.152 Undoubtedly, 
immunosuppressive therapy is crucial in order to control adverse 
events of immune checkpoint blockade, but these measures will most 
likely also interfere with beneficial anti- tumor immune responses. A 
further limitation of Ipilimumab is its known limited (tumor) tissue pen-
etration.151 Consequently, strategies to improve tumor- specific en-
richment and effectiveness of Ipilimumab would be advantageous. In 
this regard, RT and immune checkpoint blocking agents may collabo-
rate and synergize with each other. The in situ vaccinating potential of 
RT might help to increase local availability and efficacy of checkpoint 
blockade and at the same time reduce systemic complications.153–155
10.2 | Combinatorial strategies: Synergism and  
timing
Considering their closely related modes of action, the question of 
combining different immune checkpoint blockers arises immediately. 
As their individual targets differ but exert similar functions, their com-
bination might provide improved therapeutic outcome at lower doses. 
In fact, trials of combined modality approaches with Ipilimumab and 
Nivolumab reported prolonged survival in the combined treatment 
arms. However, this was linked to increased occurrence of adverse 
events, particularly high- grade toxicity.156 Therefore, the search for 
appropriate synergistic combination partners with acceptable total 
toxicity continues. Once more, RT represents an interesting candidate 
in this regard. Intriguingly, in some case reports where palliative pa-
tients often progressed under immune checkpoint blocking therapy 
alone, local and abscopal responses were observed when radiother-
apy was added.157–159
A fundamental difference between most of the radiotherapeutic 
regimens implemented in the clinical routine and the presented case 
reports of RT- induced abscopal effects is the volume of tumor and/
or metastasis mass that is irradiated. As case reports often concern 
palliative settings, the entire lesion is irradiated. Thus, upon RT an 
enormous amount of tumor antigen most likely is released compared 
to postoperative, adjuvant RT which is standard for the majority of 
cases in the clinical routine. In one case report, a biopsy sample of 
the irradiated kidney tumor was subjected to histological examination 
after manifestation of the abscopal effect.141 Excessive necrosis was 
described in this sample which might well have contributed to the ac-
tivation of anti- tumor immune responses in the sense of potent in situ 
vaccination (Figure 2).A
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11  | OBSERVATIONS IN DIFFERENT 
CANCER ENTITIES
As already mentioned, systematic analyses of the available case 
reports imply difficulties and limitations when aiming at extract-
ing a common denominator which should be considered for future 
treatment approaches in order to fully exploit the therapeutic po-
tential of RT- induced abscopal effects. Case reports from various 
cancer entities with known differences in immunogenicity have 
been published, letting it appear reasonable to discuss them sepa-
rately (Table 2). We have also tried to visualize the reported absco-
pal effects with regard to cancer entity, irradiated site, irradiation 
regimen, and site of the described abscopal effects in a schematic 
drawing (Figure 4).
11.1 | Melanoma
Ipilimumab and other immune checkpoint blockers have reached clini-
cal approval for the treatment of metastatic melanoma due to very 
convincing trial results.93,99,156 Subsequently, they have been de-
scribed in several case reports of RT- induced abscopal effects,159–164 
and the combination of RT plus checkpoint inhibition is subject of 
current clinical trials 157,165,166 (Table 3). Obviously, checkpoint inhi-
bition powerfully enforces the occurrence of RT- induced abscopal 
effects. However, this seems to be strongly dependent on the can-
cer entity, as in case of advanced prostate cancer no comparable ob-
servations have been described.167 Melanoma is a cancer with high 
mutation frequency, and this might well be responsible for the fact 
that stronger immune responses can be triggered in melanoma than 
in other cancer entities.168,169 A clinical observation which underlines 
this increased anti- melanoma activity is the development of vitiligo 
upon, e.g. Pembrolizumab treatment.170 Vitiligo is an acquired auto-
immune disease against active melanocytes resulting in depigmented 
areas of skin at different sites of the body and was shown to go along 
with better treatment outcome.170 Like abscopal responses after RT, 
in these cases vitiligo is a systemic immune effect caused by immuno-
therapy. In a case report on abscopal effects in metastatic melanoma, 
seroreactivity to melanocyte antigens was analyzed and melanoma- 
associated antigen A3 showed seropositivity after radiotherapy which 
increased even further with administration of Ipilimumab.161 Some 
trials have been set up in order to investigate the frequencies of RT- 
induced abscopal effects in melanoma and show impressive results. 
Between 25 and 52% of patients with advanced melanoma under-
going RT plus checkpoint inhibition displayed abscopal effects, and 
compared to patients without abscopal effects, they had significantly 
prolonged overall survival times.157,165,166 Although these studies 
have their limitations, the reported frequencies of abscopal effects 
are quite remarkable. Yet, these observations could be linked to the 
particular immunogenicity of malignant melanoma and may not be en-
tirely transferable to other cancer entities.
11.2 | Lymphoma
Another particular field of RT- induced abscopal effects is lymphoma. 
In 1969, M.P. Nobler was the first to describe an abscopal effect 
in malignant lymphoma (giant follicle type) and to provide careful 
F IGURE  4 Topology of abscopal effects. Available information from clinical case reports and retrospective analyses discussed in this review 
is implemented in this figure. Abscopal effects in patients with melanoma (left), lymphoma (middle), and with diverse solid tumors except 
melanoma (right) were considered. Sites of RT (bullet) and of abscopal effects (arrowhead) are indicated. Colors illustrate different irradiation 
regimens [Colour figure can be viewed at wileyonlinelibrary.com]
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TABLE  3 Selected clinical trials assessing RT- induced abscopal effects
NCT number
Study 
start date
Phase 
of Trial Tumor entity Irradiation regimen
Additional 
therapeutics
Outcome measure and 
comments
NCT03113851 04/2017 Phase II Non- small- cell lung 
carcinoma
10×3.5 Gy rhGM- CSF Abscopal effect rate assessment 
for up to 50 months, proportion 
of patients with abscopal 
effects after treatment
NCT02334709 02/2014 Phase I/
II
Renal cell carcinoma 3×8 Gy, 3×10 Gy, 
3×12 Gy
Tyrosine kinase 
inhibitor
Immunomonitoring for up to 
4 years
NCT02474186 04/2003 Phase II Breast cancer and 
other solid tumors
10×3.5 Gy Concurrent systemic 
therapy (single 
agent) and GM- CSF
Abscopal effect assessment 
7- 8 weeks after initiation of 
treatment; published in 2015 179
NCT02787447 05/2016 Phase II Non- small- cell lung 
carcinoma
40- 45 Gy, 5- 15 fr Thymalfasin, 
Gefitinib, Erlotinib, 
Icotinib
Proportion of patients with an 
abscopal response 1- 6 months 
after RT
NCT02623595 05/2016 Phase II Non- small- cell lung 
carcinoma
5×10 Gy rhGM- CSF Abscopal effect rate 4 weeks 
after completion of rhGM- CSF 
therapy
NCT01401062 07/2011 Phase II Breast cancer 3×7.5 Gy in week 1 
and week 7 given 
to two different 
lesions
Fresolimumab Abscopal effect rate assessment 
for up to 20 weeks
NCT02406183 03/2015 Phase I Melanoma 3×8 Gy, 3×10 Gy, 
3×12 Gy
Ipilimumab Immunomonitoring for up to 
2 years
NCT02830594 10/2016 Phase II Gastric, esophageal, 
and/or gastroesoph-
ageal junction cancer
Multifractionated RT Pembrolizumab Assessment of progression- free 
survival for up to 36 months
NCT02562625 02/2016 Phase II Melanoma 3×8 Gy Pembrolizumab Abscopal effect assessment for 
up to 60 months after 
randomization
NCT02976740 11/2016 Phase II Non- small- cell lung 
carcinoma
50 Gy in 4- 10 fr rhGM- CSF and 
thymalfasin
Abscopal effect rate 4 weeks 
after completion of combined 
treatment
NCT02538471 08/2015 Phase II Breast cancer 3×7.5 Gy TGF- β receptor I 
kinase inhibitor 
LY2157299
Abscopal effect assessment for 
up to 16 weeks
NCT02992912 11/2016 Phase II Solid tumors 3×15 Gy Atezolizumab Assessment of progression- free 
survival for up to 1 year
NCT01689974 01/2013 Phase II Metastatic Melanoma 5×6 Gy Ipilimumab Abscopal effect assessment
NCT02115139 04/2014 Phase II Melanoma with brain 
metastasis
10×3 Gy (WBRT) Ipilimumab Immune- related response criteria
NCT01734564 11/2012 Phase II Solid tumors n.a. Hiltonol, DC transfer Abscopal effect assessment
NCT00188929 08/2005 Phase II Non- Hodgkin’s 
lymphoma
≥30	Gy,	≥20	fr,	
≥3	weeks
None Abscopal effect assessment
NCT03085719 04/2017 Phase II Head and neck cancer 3× high- dose RT or 
3× high- dose and 
3× low- dose RT
Pembrolizumab Abscopal effect assessment for 
up to 1 year
NCT02888743 05/2017 Phase II Colorectal carcinoma 
or Non- small- cell 
lung carcinoma
High- dose or 
low- dose RT
Durvalumab, 
Tremelimumab
Abscopal tumor response rate up 
to 2 years
NCT02501473 06/2015 Phase I/
II
Follicular Non- 
Hodgkin’s lymphoma
Standard low- dose 
RT
G100 (Phase I), 
Pembrolizumab 
(Phase II)
Abscopal tumor response
NCT03150836 07/2017 Phase II Bladder cancer 5×6 Gy or 5×6.6 Gy Durvalumab, 
Tremelimumab
Abscopal effect assessment for 
up to 50 months
DC, dendritic cell; fr, fraction; rh, recombinant human; GM- CSF, granulocyte macrophage colony- stimulating factor; n.a., not available; RT, radiotherapy; rh, 
recombinant human; TGF, transforming growth factor; WBRT, whole- brain radiotherapy.
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explanations about its origin: A patient suffering from multifocal 
lymphadenopathy and bilateral hydronephrosis showed a complete 
abscopal response after paraaortic and retroperitoneal irradiation 171 
(Figure 1). With the knowledge of that time, the author explained this 
by a partial loss of lymphoma cells after irradiation followed by re-
circulation of new lymphoma cells into the irradiation field leading 
to a general decrease in lymphoma cell counts. A similar explanation 
of abscopal effects observed in lymphocytic lymphoma was given a 
few years later, thus supporting this theory of gradual lymphoma cell 
depletion.149 The first idea that the immune system could be involved 
in RT- mediated abscopal effects was presented together with several 
other theories in the context of mantle field irradiation of lymphoma 
in 1981 proposing a possible release of ‘antigens capable of stimu-
lating cytotoxicity through immune mechanisms’.145 Unfortunately, 
this concept was abandoned. More than 20 years later, a case report 
on natural killer cell lymphoma described complete regression of the 
primary lesion with appearance of a submandibular lymphadenopa-
thy after chemo- and radiotherapy. This second lesion responded 
after 2 months without further treatment, and histological analyses 
showed an increased infiltration of CD8+ T cells in the secondary le-
sion, which was not detectable in the primary lesion.147 Steady fluc-
tuation and systemic trafficking of tumor cells in many hematologic 
malignancies might explain their susceptibility to abscopal effects.145 
Therefore, generalization to other cancer entities might be rather 
limited.
11.3 | Diverse solid tumors
RT- mediated abscopal effects have been reported also for diverse 
solid tumors. Nevertheless, two entities appear to dominate: RCC 
and HCC. An interesting detail in two of the collected case reports 
is that progressive disease was observed at one site, while abscopal 
regression was simultaneously described at different other sites of the 
body.146,172 This implies that the susceptibility of some metastases to 
abscopal responses seems to be different than that of others, and it 
needs to be clarified which factors are responsible in this scenario.
11.4 | Brain lesions
Due to its particular anatomy and the blood- brain barrier, the brain’s 
accessibility for drugs and cells of the immune system underlies spe-
cific restrictions. Accordingly, the question arises if RT- mediated ab-
scopal effects with involvement of brain lesions (metastases as well 
as primary brain tumors) display certain peculiarities. Among the 
published case reports on RT- stimulated abscopal tumor regression, 
there is a number of melanoma cases with brain metastases.161–163,173 
Intriguingly, to our knowledge, so far no case report has shown ab-
scopal brain metastasis regression when peripheral lesions were ir-
radiated. On the contrary, two reports showed peripheral abscopal 
responses upon brain irradiation (whole brain RT as well as stereo-
tactic radiosurgery with and without additional immune checkpoint 
blockade).162,163 Two other reports presented similar cases, where 
abscopal effects appeared after brain radiotherapy.161,173 However, it 
needs to be considered that these patients had already received previ-
ous RT treatments in other body regions, and it cannot be specified 
if the abscopal effects were primarily due to brain irradiation or the 
preceding RT. Although these reports have their limitations, it appears 
that abscopal effects can be stimulated by irradiation of brain lesions, 
whereas irradiation of peripheral nodules vice versa fails to stimulate 
abscopal lesion regression in the brain.
12  | CELLULAR AND MOLECULAR 
PARAMETERS IN PATIENTS WITH  
RADIOTHERAPY- INDUCED 
ABSCOPAL EFFECTS
Although patients with RT- induced abscopal effects represent a 
rather heterogeneous group, they exhibit common features—not only 
clinically, but also on a cellular and molecular level. However, since 
abscopal responses are generally not expected a priori, all analyses 
were performed retrospectively, and systematic prospective evalua-
tions are not available.
In the well- known case report by Postow et al.,159 abscopal lesion 
regression in a patient with metastatic melanoma upon RT in combina-
tion with Ipilimumab treatment was accompanied by increased serum 
antibody titers against the tumor antigen NY- ESO- 1. Additional flow 
cytometric analyses revealed elevated expression of MHCII on circu-
lating monocytes and a decline in circulating MDSCs. Moreover, levels 
of activated circulating CD4+ICOShi T cells showed an intense in-
crease. Golden et al. investigated the dynamics of blood cell counts in 
an abscopally responding patient with NSCLC and found peaks in leu-
kocytes, lymphocytes, and eosinophils directly after the start of con-
comitant radioimmunotherapy with Ipilimumab. Simultaneously, levels 
of the tumor marker CEA increased, went through a maximum (indicat-
ing tumor cell disintegration), and afterward decreased to background 
levels. In order to compare nodal metastases, extirpation of abscopal, 
tumor- bearing lymph nodes was performed before and after therapy. 
In contrast to the lymph node that was excised before RT, the one ex-
tirpated postirradiation showed lymphocytes invading tumor regions, 
increased infiltration of CD8+ T cells, an enhanced CD8+/FoxP3+ T- cell 
ratio, and more cytotoxic granules.174 A correlation between clinical 
benefit and peripheral blood cell counts was demonstrated by Tang 
et al.: Patients showing abscopal responses upon radioimmunotherapy 
with Ipilimumab and RT of lung or liver metastases were analyzed for 
peripheral blood cell populations. Whereas high numbers of CD8+ T 
cells as well as high CD8+/CD4+ T- cell ratios correlated with increased 
clinical benefit, high CD4+ counts failed to do so.175 Nakanishi et al. 
investigated cytokine serum levels of an abscopally responding HCC 
patient before and after RT and reported increases in IL- 1β, IL- 4, and 
IL- 6.176 Finally, Teulings et al. performed immunological analyses of 
lymph node and brain metastases of a melanoma patient with absco-
pal tumor regression upon whole brain RT and described the presence 
of CD8+ T cells and antibody reactivity against melanocyte differenti-
ation antigens expressed in the primary tumor, lymph node, and brain 
metastasis indicating T cell- mediated anti- melanoma activity.173 In 
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summary, these reports provide clinical evidence for the concept of 
RT- mediated in situ vaccination and the specific importance of CD8+ 
T- cell responses as has already been discussed for the preclinical 
model systems. However, critical prospective evaluation is necessary 
in order to identify and characterize reliable molecular markers of RT- 
mediated abscopal immune effects which are of predictive value and 
can serve for monitoring purposes in the future.
13  | CLINICAL TRIALS AND RETROSPECTIVE 
ANALYSES WITH FOCUS ON ABSCOPAL  
RESPONSES
Although RT- mediated abscopal effects are rather rare phenomenona, 
a number of case reports as well as common characteristics among 
them suggest that distinct factors contribute to their appearance. 
While early case reports were rather anecdotal stories of individual 
patients, recent studies present retrospective analyses of dozens of 
patients—a fact that could derive from an increased occurrence of 
abscopal effects due to enhanced implementation of combined mo-
dality RT (including checkpoint inhibition), sharpened interest in RT- 
induced abscopal effects, and/or more frequent detection as a result 
of improved imaging techniques. Nonetheless, systematic analyses of 
out- of- field responses are lacking, and existing studies mostly have 
limitations in cohort sizes and treatment groups, among others. The 
exploitation of abscopal effects as endogenous weapons in cancer 
treatment seems highly attractive, but the underlying mechanisms as 
well as the details of treatment regimens, including timing, dosing, and 
combination strategies, clearly need further investigation.
A retrospective analysis underlining the increased efficacy of RT 
plus checkpoint inhibition in melanoma patients with brain metasta-
ses showed that in comparison to patients without Ipilimumab after 
RT, patients treated with Ipilimumab displayed improved overall sur-
vival (5.3 vs 18.3 months).177 However, some control group patients 
received RT plus Bortezomib which limits interpretation. Interestingly, 
patients undergoing stereotactic radiosurgery revealed better re-
sponses compared to patients with whole brain RT implying a certain 
advantage of RT regimens with higher doses. However, another ret-
rospective analysis which directly compared stereotactic radiosurgery 
with and without additional Ipilimumab treatment in patients with mel-
anoma brain metastases could not confirm this. The authors did also 
not observe differences depending on the time point of Ipilimumab 
administration.178
A prospective clinical trial with patients with different metastatic 
cancers (stable or progressing on single- agent chemotherapy or hor-
monal therapy) undergoing RT plus GM- CSF treatment described an 
abscopal effect rate of 25% (11 of 41 patients) 179 (NCT02474186). 
Importantly, the authors reported significantly prolonged overall 
survival for patients with out- of- field responses compared to those 
with no abscopal response (median overall survival 8.33 months 
vs 20.98 months, hazard radio 2.06). This trial did not include clas-
sic immunomonitoring but identified a low baseline neutrophil/
lymphocyte ratio as predictor of RT- induced abscopal responses. 
Yet, the mechanisms behind this remain elusive, and more in- depth 
analyses are needed in this regard. GM- CSF was chosen as an agent 
which can stimulate DC activation and cross- presentation. However, 
the authors argue that T- cell exhaustion might limit long- term anti- 
tumor immunity, and therefore suggest systematic trial approaches 
to evaluate immune checkpoint inhibition in combination with RT.179 
This is the focus of several ongoing clinical trials (Table 3). As an ex-
ample, the KEYNOTE- 001 trial investigated the efficacy and toxicity 
of Pembrolizumab treatment for patients with advanced NSCLC 180 
(NCT01295827). A secondary analysis of this trial focused on the 
role of previous RT in the treatment history.181 Intriguingly, patients 
who had previously received RT showed longer progression- free 
survival upon Pembrolizumab treatment than patients who had not 
(4.4 months vs 2.2 months, hazard ratio 0.56), and previous RT was 
identified as an independent predictor in this regard. Similar results 
were obtained for the analysis of overall survival. Despite these en-
couraging observations, patients with prior RT also experienced more 
treatment- related toxicities. Nevertheless, the numbers of high- grade 
toxicities were similar between both groups. So, immune checkpoint 
blockade and RT apparently are powerful partners, but careful super-
vision of potential toxicities needs to be ensured. Accordingly, the re-
sults of other ongoing trials are eagerly awaited—not only with regard 
to treatment outcome and toxicity, but also in view of recommenda-
tions for treatment details, including timing and dosing, and the identi-
fication of suitable predicting and monitoring markers.
14  | THE PERSISTING GAP BETWEEN 
CLINICAL AND PRECLINICAL  
OBSERVATIONS
For decades, abscopal tumor regression has been an extremely rare 
and nearly mysterious phenomenon which was observed in very few 
patients, and only some but by far not all determinants of this effect 
have been elucidated by now. With the advent of immunotherapies, 
the view on RT- induced abscopal effects has gradually changed, but 
many clinicians still do not consider distant tumor regression in re-
sponse to local RT as a reasonable therapeutic aim but rather as an 
incidental side benefit in a very limited set of patients. In contrast, 
our knowledge about the mediators in this context is largely based 
on preclinical animal models, where IR- dependent out- of- field tumor 
regression can be generated reproducibly with a given treatment. As 
discussed before, these preclinical models fundamentally contributed 
to our understanding of RT- stimulated abscopal responses. However, 
several aspects in this field are still not sufficiently addressed and 
other findings lack translational relevance. Most importantly, we are 
about to reach a point where it is no longer sufficient to simply dem-
onstrate once more that abscopal effects can be generated in a given 
mouse model. Instead, the time is overdue to test novel therapeutics 
and treatment approaches for their efficacy in combination with RT 
to stimulate abscopal effects using clinically relevant treatment regi-
mens in animal models which closely mimic the clinical situation in 
the patient.
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Considering the RT regimen, there is an obvious discrepancy be-
tween preclinical findings and the clinical routine (Figure 5): Whereas 
about half of the preclinical reports employed high (ablative) single IR 
doses of up to 60 Gy for the activation of anti- tumor immunity, cli-
nicians commonly use smaller single doses, hypofractionated treat-
ments, or classically fractionated protocols, respectively, because 
higher doses bear the risk of increased side effects. Interestingly, most 
case reports of RT- induced abscopal responses are associated with pal-
liative irradiation schemes where higher single doses were employed, 
and retrospective analyses also support the idea that increased sin-
gle doses might be beneficial with regard to their immunostimulating 
potential.159,177 Hence, basic and clinical research may consider the 
question whether RT- induced abscopal effects are rarely seen in the 
clinical routine because of a preponderance of immunologically less 
effective irradiation regimens. In this regard, it should again be empha-
sized that local RT per se is by far not always immune activating, since 
various immune cell populations—including lymphocytes—are known 
to decline temporarily after standard RT treatments.36,37 Another issue 
regarding the RT regimen that needs to be discussed is the localization 
of the lesion that should be irradiated in order to stimulate abscopal 
responses when a patient presents with multiple nodules. At first sight, 
analysis of the available literature does not allow absolute conclusions. 
However, we could not find a single report in which abscopal regres-
sion of brain lesions was observed upon irradiation of tumors and/or 
metastases in peripheral organs (Figure 4, Table 2). Clearly, this needs 
further in- depth examination.
Second, the gap between preclinical findings and clinical expe-
riences might be narrowed by fully exploiting the available animal 
models used for studies of RT- mediated stimulation of anti- tumor im-
munity. We found only two publications employing orthotopic synge-
neic mouse models in this regard: Zeng and coworkers demonstrated 
a T cell- dependent impact on survival of RT in combination with 
PD- 1 blockade in mice bearing intracranial murine glioblastomas,59 
and Young et al. reported a significant reduction in pancreatic tumor 
growth and an increase in T- cell infiltration upon RT in combination 
with TGF- β inhibition.58 Astonishingly, truly every preclinical finding 
on RT- induced distant tumor growth inhibition in immunocompetent 
mice derives from heterotopic subcutaneous or intramuscular tumors 
and—at least to our knowledge—not a single orthotopic or autoch-
thonous model has ever been employed to study immune- mediated 
abscopal effects of irradiation. This brings up the provocative ques-
tion whether immune- mediated distant tumor regression can only be 
reproducibly instigated by RT in preclinical model systems with sub-
cutaneous tumors but not with orthotopic tumor transplants, or au-
tochthonous tumors, respectively. Although this is hopefully not the 
case, there is an obvious need to address this unresolved issue, since 
massive differences between growth characteristics and therapeutic 
responses of autochthonous, orthotopically, and heterotopically grow-
ing tumors are well- known.55,182
Finally, the treatment sequence is another obvious difference be-
tween preclinical models reproducibly showing abscopal anti- tumor 
effects and the clinic where RT- induced distant tumor regression is 
F IGURE  5 Major determinants 
influencing the occurrence and observation 
of radiotherapy-mediated abscopal 
effects [Colour figure can be viewed at 
wileyonlinelibrary.com]
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still quite rare (Figure 5): Reportedly, RT can generate in situ cancer 
vaccines, including antigen material and immunostimulating adjuvants, 
via the induction of immunogenic forms of cell death in the tumor. 
However, the effective priming of anti- tumor immune responses is 
also dependent on the influences of other therapeutic measures. As 
such, preceding surgery defines the amount of tumor mass that is ir-
radiated as well as the presence or absence of lymph nodes which 
are needed for proper interactions between DCs and T cells. Whereas 
many patients undergo surgery of both their tumor and its draining 
lymph nodes before adjuvant RT, in preclinical settings RT is usually 
administered to the subcutaneous bulk tumor without any preceding 
surgery. Consequently, the antigenic load liberated from billions of 
dying and/or damaged tumor cells in the irradiated experimental tu-
mors is magnitudes higher than in a clinical situation where only very 
few tumor cells remain after successful surgery. Hence, it would be 
interesting to elucidate whether the strength of inducible anti- tumor 
immunity and abscopal effects in preclinical model systems is depen-
dent on the irradiated tumor’s volume as has already been suggested 
by J. Vaage years ago.61 If this is the case, it would also explain why 
abscopal effects in the clinic are commonly observed in metastasized 
situations where surgery is no longer indicated. For clinical translation, 
this would imply that neoadjuvant concepts with several RT fractions 
prior to surgery might be considered where applicable. Furthermore, 
the impact of lymph nodes in this setting also needs to be evaluated in 
order to elucidate whether their surgical removal prior to RT decreases 
systemic anti- tumor immunity in patients owing to inefficient T- cell 
(cross- )priming. In this regard, it has already been reported that tumor- 
draining lymph nodes are indispensable for T- cell priming and tumor 
growth inhibition in response to RT.45 Thus, we carefully propose to 
elucidate whether the time point of lymph node and bulk tumor re-
moval relative to RT could be optimized in order to make abscopal 
tumor regression more likely. Besides, many cancer patients are co- 
treated by chemotherapy. Extensive work from the Kroemer group has 
elegantly demonstrated the hitherto unknown immunogenic effects 
of several chemotherapeutic agents,3,113,115,117,183 thus rendering 
them highly attractive for combination with RT in order to strengthen 
abscopal anti- tumor immunity. However, concurrent chemotherapy 
can also interfere with immune cell viability and function due to its 
well- known immunosuppressive side effects. Accordingly, clinically 
established treatment protocols should be (re- )evaluated since various 
chemotherapeutic regimens showed conflicting results with regard 
to posttherapy T- cell functionality in the clinic.184–187 This also raises 
the question whether clinical failure of chemotherapy and/or RT reg-
imens can partly be attributed to the fact that immunogenic forms 
of cell death are either absent or insufficient to positively influence 
the clinical outcome in distinct patients, since immune cell recovery 
may be strongly impeded after local RT and especially after systemic 
chemotherapy. Hence, both RT and chemotherapy regimens may re-
quire immunological fine- tuning in order to fully exploit their immune 
activating potential. Finally, immunotherapy can help to unleash anti- 
tumor immune responses, but again correct timing appears crucial. So, 
complex interactions, mutual reinforcement and/or interference, as 
well as parallel effects raise the question of how to ideally combine 
these therapeutic measures. Unfortunately, only limited data are avail-
able in this regard, and more studies focusing on optimizing the thera-
peutic sequence are needed.
Considering that the great advances in modern cancer therapy 
were only possible due to gradually improving the interplay between 
surgery, RT, chemotherapy, molecularly targeted therapy, and immu-
notherapy, it is already evident that this will by no means question the 
crucial importance of any of the involved disciplines but rather shed 
light on the issue of their optimal therapeutic interplay with the aim of 
achieving the best therapeutic outcome for every individual patient. 
We are convinced that our understanding of RT- induced abscopal ef-
fects will increase rendering their therapeutic potential exploitable on 
a regular basis if, on the one hand, preclinical researchers address the 
aforementioned clinically relevant problems in suitable animal models 
with clinically relevant treatment regimens and if, on the other hand, 
clinicians carefully reflect these findings in order to fine- tune and to 
reconsider the clinically established treatment protocols. Besides, bio-
informatic approaches have been proposed as a means to improve our 
understanding of abscopal tumor regression by integrating preclinical 
and clinical data into mathematical models.189,190 However, due to the 
obvious limitations in biological and clinical information available at 
present, it is questionable whether these models will offer any reliable 
conclusions for the clinic at this early stage.
In spite of the aforementioned challenges, a systematic clinical 
evaluation of RT- induced abscopal effects has already begun, and 
clinical trials have been set up for metastatic neoplasms of different 
origins such as breast cancer (NCT01401062, NCT02538471), RCC 
(NCT02334709), melanoma (NCT02406183, NCT02562625), lym-
phoma (NCT02501473), and NSCLC (NCT02623595) (Table 3). These 
trials are important examples of efforts to narrow the gap between 
preclinical and clinical findings as hypofractionated RT regimens with 
three to five single doses of 6 to 12 Gy in combination with immuno-
modulatory drugs such as PD- 1 or CTLA- 4 blockade, TGF- β inhibition, 
tyrosine kinase inhibitors, and GM- CSF are employed. One remaining 
issue that will also be addressed in these trials is the identification 
of predictive and follow- up markers which will help to select suitable 
subgroups of patients and can serve for proper monitoring (Figure 5).
15  | CONCLUSIONS
Abscopal effects of RT have a long- standing history and have made 
their way through anecdotal case reports and preclinical evaluation. 
Despite still being rare observations in the radiotherapeutic routine, 
interests in their therapeutic application are constantly increasing—
particularly since the clinical implementation of immunotherapeu-
tic approaches, as meanwhile it is well acknowledged that systemic 
anti- tumor immune mechanisms are the underlying driving forces 
of RT- induced out- of- field lesion regression. We are convinced that 
narrowing the gap between clinical and preclinical experiences is 
achievable, and we want to encourage preclinical researchers to criti-
cally scrutinize their model systems and treatment regimens with re-
spect to clinical relevance, as well as clinicians, in turn, to carefully 
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reconsider established treatment protocols in view of timing and dos-
ing. The number of clinical trials which are currently being initiated 
clearly indicates that abscopal effects are no longer considered as ex-
perimental artifacts but instead as clinically exploitable phenomenona 
which might broaden the scope of cancer therapy in the near future.
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